PharmaLectures.com

Courses › Pharma training by country › Korean companies that cracked Europe, and what they did differently

Korean companies that cracked Europe, and what they did differently

Your team files European dossiers that answer the assessor before the question comes.

  • 5 audio modulesthree lengths each
  • 50 min to 4 h 10 minbriefing to expanded
  • Workbook, transcript, certificateand a recorded quiz per module
  • Korea companieswho it is written for

Why this training matters

A gap in your Marketing Authorisation Application brings a list of questions from the European Medicines Agency and stops the clock. Your regulatory team rewrites for months while a competitor launches its biosimilar. The launch window you planned for closes.

What changes after this course

Your regulatory staff builds dossiers that answer the assessor's likely questions before they are asked. Quality, clinical and safety colleagues work from the same European rules. You hold a certificate per learner and a training record for each person, ready for your next audit.

Watch the pitch

3:43 on how an audio course is bought, listened to and recorded. Full screen, one click.

Watch the pitch3:43, full screen, one click

What this course gives your people

Your regulatory affairs team files the Marketing Authorisation Application without a week of doubt about the format. They know when the Centralised Procedure applies and what Directive 2001/83/EC expects in each section. The assessor reviewing the application finds the answer where they look first, so fewer questions come back.

The quality assurance unit stops dreading the call that says an inspector is coming. They bring the Site Master File into line with EudraLex Volume 4, the European Union Good Manufacturing Practice rules, and close the gaps before the pre-approval inspection opens them. The Qualified Person gets the batch paperwork that lets imported product move.

Clinical operations staff turn non-European trial results into Module 2 and Module 5 of the Common Technical Document without paying a consultant to reformat them. They write the Clinical Overview from your Korean data. When a reviewer asks for clarification, the reply is one page, not a project.

Pharmacovigilance officers report suspected serious adverse reactions to the EudraVigilance database inside the legal deadline and can show the record. When a national competent authority inspects, the answers come straight from Module I of Good Pharmacovigilance Practices. Business development then negotiates partnerships with a clear view of which regulatory roles to keep and which to share.

Who needs this training

  • Regulatory Affairs Manager

    The application comes back for rework after the first check. They get the dossier structure and Centralised Procedure rules that let the next submission pass without a rewrite.

  • Quality Assurance Director

    A European inspector announces a visit, and the Site Master File is out of date. They align it with EudraLex Volume 4 before the inspector arrives.

  • Clinical Operations Lead

    Korean study reports do not fit the Common Technical Document headings, and the deadline is close. They place each result in Module 2 or Module 5 the way reviewers expect.

  • Pharmacovigilance Officer

    A suspected serious adverse reaction comes in from a European patient and the clock is running. They know what goes to the EudraVigilance database, when, and what the inspector will ask to see.

  • Business Development Manager

    A European distributor sends a draft agreement. They compare it with partnership structures Korean biosimilar firms already use, and know which terms to settle first.

Roles: Owner, CEO and board, Business development and export sales

Businesses: every kind of pharma company

Countries: Korea

Selling into: Europe and the UK

Courses are in English. Other languages on request.

After this course your people can

  1. Decide whether a medicine must go through the Centralised Procedure and check a Marketing Authorisation Application against Directive 2001/83/EC before submission.
  2. Update a Site Master File so it matches EudraLex Volume 4 and answers an inspector's first questions.
  3. Place Korean clinical data in the right sections of Module 2 and Module 5 of the Common Technical Document.
  4. Write a Clinical Overview that points a European assessor to the supporting study reports.
  5. Report a suspected serious adverse reaction to the EudraVigilance database inside the legal deadline.
  6. Show an inspector the records that prove your pharmacovigilance system follows Module I of Good Pharmacovigilance Practices.
  7. Choose which regulatory responsibilities to keep and which to give a European partner, and settle them in the agreement.

What the company gets

  • Your regulatory team submits the Marketing Authorisation Application in a format the European Medicines Agency can assess without a first round of avoidable questions.
  • The quality department holds a Site Master File that matches EudraLex Volume 4, ready to hand to an inspector the day the notice arrives.
  • Your safety team answers inspector questions from Module I of Good Pharmacovigilance Practices, with records to back each answer.
  • Business development brings partnership terms that other Korean biosimilar firms already use, so negotiations start from a tested position.
  • You hold a certificate and a training record for each learner, so the file for your next audit is complete.

The evidence: questionnaire, training record, certificate

EU GMP Chapter 2, section 2.11, and 21 CFR 211.25 both ask for training that is documented and shown to work. This is what each learner leaves behind.

A recorded questionnaire per module

Every one of the 5 modules ends with a multiple-choice questionnaire. The result is recorded per person with a timestamp, whichever of the three lengths the person listened to.

A per-person training record

The export lists each learner, each module, the result and the date, which is the training record EU GMP Chapter 2 and 21 CFR 211.25 ask you to keep and the first thing an inspector asks for.

A certificate per learner

Name, company, course, hours, the guideline version taught and the date. It documents in-company training; it is not a professional qualification or an accreditation.

Your pass mark, your rule

There is no fixed pass mark. Your quality or human-resources manager decides what counts as passed and when a module is retaken, exactly as your training procedure says.

Delivered within 72 hours of payment, with the workbook, the full transcript and a source for every fact in the audio.

How long it takes, by who is listening

Nobody spends a day in a classroom. Every module exists in three lengths; a person takes the length their role needs, and every length ends with the same recorded questionnaire, so the training record is complete either way.

Briefing50 min10 min a module, for executives, sales and anyone who must know the rules, not run them
Standard2 h 05 min25 min a module, for regulatory, quality and business-development staff
Expanded4 h 10 min50 min a module, for technical staff who run the procedure day to day
Who takes this courseLengthTotal time
Owner, CEO and boardBriefing50 min
Business development and export salesBriefing50 min

Course outline: 5 modules

5 modules. Under each title are the three things the listener can do afterwards; the audio itself runs 10 to 50 minutes depending on the length chosen.

  1. 1Submit a dossier that clears European Medicines Agency review

    • Why a dossier that follows Directive 2001/83/EC still draws questions, and how to close them first.
    • How to tell, before you write a page, whether your medicine must use the Centralised Procedure.
    • What to check before submission so your application passes validation and starts its review clock.
  2. 2Align your quality system with EudraLex Volume 4 Good Manufacturing Practice

    • What to do when an inspector asks for your Site Master File and it no longer matches the site.
    • The EudraLex Volume 4 gaps that stall a pre-approval inspection, found before the inspector finds them.
    • How to prepare the paperwork a Qualified Person needs so an imported batch is not held.
  3. 3Format non-European clinical data for the Common Technical Document

    • How to present Korean trial results so a European assessor finds the answer in the first place they look.
    • The data that belongs in the Clinical Overview in Module 2, and what stays in Module 5.
    • When Korean study reports need rework for Module 5 and when they can go in as they are.
  4. 4Pass inspections using European Union Good Pharmacovigilance Practices

    • When a suspected serious adverse reaction must reach the EudraVigilance database, and who sends it.
    • What to do when a national competent authority announces a pharmacovigilance inspection of your company.
    • The Good Pharmacovigilance Practices Module I records that prove your safety system works.
  5. 5Copy the partnership structures Korean biosimilar firms use in Europe

    • How Korean biosimilar firms split roles with European partners, and which role you should keep.
    • Why a distribution agreement should settle regulatory responsibilities before it settles price.
    • The early mistakes that delay a first European launch, so you skip them.
The founders

One of us was inspected. The other one pays for the training.

Every claim below is sourced on the about page: the medicines register, the Lithuanian Pharmaceutical Union board list, the university directory.

Justina Krukonytė-Racz

Justina Krukonytė-Racz

Co-founder. Licensed pharmacist.

GDPResponsible PersonWarehouse & logistics

Licensed pharmacist. Responsible Person at Tamro (PHOENIX group), where she led the GDP set-up of the distribution centre.

The Responsible Person is the named person the regulator holds accountable for every pallet that leaves the building.

She writes the modules around the procedures a GDP inspection checks. Board member of Lithuanian Pharmaceutical Union.

Listed in the Lithuanian medicines register as Pharmacist.

Prof. Ben Racz

Prof. Ben Racz

Co-founder. Builds the platform and is responsible for delivery, records and pricing.

Platform & deliveryQuantitative researchCarnegie Mellon

He was Professor of the Practice at the College of Engineering at Carnegie Mellon University, where he taught Advanced Quantitative Finance and Algorithmic Trading to MSc students.

He is the founder and Managing Director of Algorithmic Sciences, a scientific research and consulting firm. Earlier he co-founded a data-driven growth consultancy, a data-science based wholesale trading company and an information security firm.

More about Ben at benracz.com

Questions about this course

Is there a certificate?

Yes. Every learner who finishes the course receives a certificate in their own name, and every module ends with a recorded multiple-choice questionnaire, so the certificate sits on top of a per-person training record. The certificate documents in-company training; it is not a professional qualification or an accreditation, and your quality or human-resources manager sets the pass mark and decides when a module is retaken.

How long does the course take?

5 modules, each in three lengths: a 10-minute briefing, a 25-minute standard run and a 50-minute expanded walk-through. The whole course takes 50 min in the briefing length and 4 h 10 min in the expanded length. People take the length their role needs, and every length ends with the same recorded questionnaire, so the training record is complete either way.

Who should take this course?

It is written for Korea companies. Owners, managers and sales staff hear the briefing length, regulatory, quality and business-development staff take the standard run, and the people who run the procedure every day get the expanded version. One licence covers one named person on this course for a year, so the same title can be rolled out across a whole team at once.

Is this training accepted as a GMP training record by an auditor?

EU GMP Chapter 2 and 21 CFR 211.25 require documented, effective training, and that is what the course produces: a recorded multiple-choice result per module and per person, a certificate per learner and a transcript of what was taught. No provider can promise acceptance by a specific inspector; the record is built to answer what inspectors ask for, and your quality manager decides the pass mark.

How is it delivered and how fast?

The course arrives as audio files with a companion workbook, a full transcript and the questionnaire per module, within 72 hours of your payment arriving. You host the files on your own system or share them as you like; there is no platform to log into and no learner management system to set up. The free sample module arrives on request, before any purchase.

What does it cost per learner?

The list price is 9 euros per module, per learner, per year, so this course is 45 euros for one person for twelve months. The price per learner falls as more people take the same course: 10 learners pay 10 percent less and the discount keeps growing to 50 percent at 1000 learners. Type a number on the price panel and the yearly total appears.

Get this course for your team

One licence is one person on this course for a year. All three lengths, the workbook, the certificate and the training record are included in every purchase. Pick how many people, add it to the cart, and you have an invoice in your inbox.

Free sample module

Hear one full module before you spend a cent. Send your company and the role you want trained, and a complete sample module comes back with its workbook and transcript.

Connect on WhatsApp

or email [email protected], or ask for a written quote for your team